Febuxostat

From Wikipedia, the free encyclopedia

Febuxostat
Systematic (IUPAC) name
2-(3-cyano-4-isobutoxyphenyl)-4-methyl-
1,3-thiazole-5-carboxylic acid
Identifiers
CAS number 144060-53-7
ATC code M04AA03
PubChem 134018
Chemical data
Formula C16H16N2O3S 
Mol. mass 316.374 g/mol
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Licence data

EU
Pregnancy cat.

?
Legal status
Routes  ?

Febuxostat (INN; brand name Adenuric) is an inhibitor of xanthine oxidase for the treatment for gout.[1]

It was approved by the European Medicines Agency on April 21, 2008.[2]

[edit] References

  1. ^ Stamp LK, O'Donnell JL, Chapman PT (2007). "Emerging therapies in the long-term management of hyperuricaemia and gout". Internal medicine journal 37 (4): 258–66. doi:10.1111/j.1445-5994.2007.01315.x. PMID 17388867. 
  2. ^ Adenuric® (febuxostat) receives marketing authorisation in the European Union. Retrieved on 2008-05-28.

[edit] External links

v • d • e
Antigout preparations (M04)
Uricosuric
Other
Allopurinol, Cinchophen, Colchicine, Febuxostat, Oxypurinol
 This biochemistry article is a stub. You can help Wikipedia by expanding it.
Languages